N-(4-formyl-phenyl)-succinamic acid | 22042-74-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(4-formyl-phenyl)-succinamic acid
• 英文别名: N-(4-Formyl-phenyl)-succinamidsaeure；4-[(4-Formylphenyl)amino]-4-oxobutanoic acid；4-(4-formylanilino)-4-oxobutanoic acid
• CAS: 22042-74-6
• 化学式: C₁₁H₁₁NO₄
• 分子量: 221.213
• InChiKey: MUTQKWRNRQUYEJ-UHFFFAOYSA-N

物化性质

• 熔点：
  226 °C(Solv: ethanol (64-17-5))
• 沸点：
  532.4±35.0 °C(Predicted)
• 密度：
  1.367±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  83.5
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  苯硫代甲酰肼 、 N-(4-formyl-phenyl)-succinamic acid 以 乙醇 为溶剂， 生成 Bernsteinsaeure-mono-<4-(thiobenzoylhydrazono-methyl)-phenylamid>
  参考文献：
  名称：

  Jensen,K.A.; Pedersen,C., Acta Chemica Scandinavica (1947), 1961, vol. 15, p. 1097 - 1103

  摘要：

  DOI：
• 作为产物：
  描述：

  丁二酸酐 、 对氨基苯甲醛 生成 N-(4-formyl-phenyl)-succinamic acid
  参考文献：
  名称：

  Antituberculous Compounds. II. 2-Benzalhydrazinobenzothiazoles^1a

  摘要：

  DOI：

  10.1021/ja01152a132

文献信息

• [EN] DIPHOSPHONATE DERIVATIVES OF THERAPEUTIC AGENTS<br/>[FR] DERIVES DIPHOSPHONATE D'AGENTS THERAPEUTIQUES
  申请人：ELIZANOR BIOPHARMACEUTICALS, INC.

  公开号：WO1996040190A1

  公开（公告）日：1996-12-19

  (EN) Novel chemotherapeutic agents having utility in treating infectious diseases such as periodontal disease, certain urinary tract infections, infectious urinary tract stones, and bone cancer, are obtained by combining chemically a diphosphonate compound with a therapeutic agent effective against the foregoing diseases.(FR) Nouveaux agents chimiothérapeutiques convenant au traitement de maladies infectieuses telles que les parodontoses, certaines infections des voies urinaires, les calculs infectieux des voies urinaires et le cancer des os, et obtenus par l'association chimique d'un composé diphosphonate avec un agent thérapeutique agissant efficacement contre les maladies précitées.

  (中) 通过将二膦酸盐化合物与对牙周病、某些尿路感染、感染性尿路结石和骨癌等感染性疾病有效的治疗药物化学结合，获得了在治疗上具有实用价值的新型化疗药物。
• Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors
  作者：Aviv Gazit、Pnina Yaish、Chaim Gilon、Alexander Levitzki

  DOI：10.1021/jm00130a020

  日期：1989.10

  A novel class of low molecular weight protein tyrosine kinase inhibitors is described. These compounds constitute a systematic series of molecules with a progressive increase in affinity toward the substrate site of the EGF receptor kinase domain. These competitive inhibitors also effectively block the EGF-dependent autophosphorylation of the receptor. The potent EGF receptor kinase blockers examined were found to competitively inhibit the homologous insulin receptor kinase at 10(2)-10(3) higher inhibitor concentrations in spite of the significant homology between these protein tyrosine kinases. These results demonstrate the ability to synthesize selective tyrosine kinase inhibitors. The most potent EGF receptor kinase inhibitors also inhibit the EGF-dependent proliferation of A431/clone 15 cells with little or no effect on EGF independent cell growth. These results demonstrate the potential use of protein tyrosine kinase inhibitors as selective antiproliferative agents for proliferative diseases caused by the hyperactivity of protein tyrosine kinases. We have suggested the name "tyrphostins" for this class of antiproliferative compounds which act as protein tyrosine kinase blockers.
• Jensen; Jensen, Acta Chemica Scandinavica (1947), 1952, vol. 6, p. 957
  作者：Jensen、Jensen

  DOI：——

  日期：——
• GAZIT, AVIV;YAISH, PNINA;GILON, CHAIM;LEVITZKI, ALEXANDER, J. MED. CHEM., 32,(1989) N0, C. 2344-2352
  作者：GAZIT, AVIV、YAISH, PNINA、GILON, CHAIM、LEVITZKI, ALEXANDER

  DOI：——

  日期：——
• DIPHOSPHONATE DERIVATIVES OF THERAPEUTIC AGENTS
  申请人：ElizaNor Biopharmaceuticals, Inc.

  公开号：EP0831845B1

  公开（公告）日：2004-09-08